Use: Labeled indications
- NEVANAC ® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE NEVANAC ® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery. (1)
Contraindications
4 CONTRAINDICATIONS NEVANAC 0.1% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDs). Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDS). (4)
US FDA labelDosing: Adult
One drop of NEVANAC should be applied to the affected eye three times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. (2.1)
2.1 Recommended Dosing
2.1 Recommended Dosing One drop of NEVANAC 0.1% should be applied to the affected eye three times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. Shake the container well prior to dosing.
2.2 Use With Other Topical Ophthalmic Medications
2.2 Use With Other Topical Ophthalmic Medications NEVANAC 0.1% may be administered in conjunction with other topical ophthalmic medications, such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics. If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of NEVANAC 0.1% in pediatric patients below the age of 10 years have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Sterile ophthalmic suspension: 1 mg/mL, 3 mg/mL
- Ophthalmic suspension: 1 mg/mL
Registered products in the Philippines
7 products registered with the Food and Drug Administration (FDA) Philippines list Nepafenac as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products7
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
IlevroNepafenac | 3 mg/mL (0.3 % w/v) Sterile Ophthalmic SuspensionKeep the bottle in the outer carton in order to protect from light. : LDPE Plastic Bottle with PP closure x 3 mL (Box of 1's) | Rx | Alcon-Couvreur NVBelgium | Importer: Novartis Healthcare Philippines, Inc. | DR-XY 47806 | Mar 10, 2027 | |
NepalactNepafenac | 1 mg/mL (0.1% w/v) Sterile Ophthalmic Suspension (Eye Drops)5 mL (net content) translucent LDPE dropper bottle with translucent LDPE plug and opaque white HDPE pilfer-proof cap Box of 1's | Rx | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DR-XY45971 | Aug 1, 2032 | |
NepanacNepafenac | 1mg/mL (0.1% w/v) Sterile Ophthalmic SuspensionLDPE Dropper Bottle with PP Nozzle and PVC Cap x 15mL (Box of 1's) | Rx | Remington Pharmaceutical Industries (Pvt.) Ltd.Pakistan | Ophthamed Pharma Corp. | DRP-12265 | Jun 23, 2031 | |
NepasightNepafenac | 1mg/mL Ophthalmic SuspensionWhite LDPE Bottle x 5mL (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd. | DR-XY49585 | Nov 14, 2031 | |
NevanacNepafenac | 1 mg/mL (0.1% w/v) Sterile Ophthalmic SuspensionLDPE round plastic droptainer x 5 mL | Rx | Aleon-Couvreur NVBelgium | Novartis Healthcare Philippines | DR-XY32292 | Sep 25, 2027 | |
NeypacNepafenac | 1 mg/mL (0.1% w/v) Sterile Ophthalmic Suspension (Eye Drops)5 mL-net content white translucent round LDPE vial with spike cap (Box of 1's) | Rx | Axa Parenterals LimitedIndia | S.M.H.P. Marketing & Consultancy | DR-XY48992 | Jan 26, 2029 | |
OptanepNepafenac | 3 mg/ mL (0.3% w/v) Sterile Ophthalmic Suspension5 mL White opaque LDPE bottle with LDPE/HDPE cap and LDPE dropper (Box of 1's) | Rx | World Medicine Ilaç Sanayi ve Ticaret A.Ş.Turkey | Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc. | DR-XY48307 | Aug 22, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Sterile ophthalmic suspension 0.1% 3 mL in a 4 mL bottle Sterile ophthalmic suspension 0.1% 3 mL in a 4 mL bottle (3)
Warnings/Precautions
- Increased bleeding time due to interference with thrombocyte aggregation (5.1)
- Delayed Healing (5.2)
- Corneal effects, including keratitis (5.3)
5.1 Increased Bleeding Time
5.1 Increased Bleeding Time With some NSAIDs, including NEVANAC 0.1%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery.
It is recommended that NEVANAC 0.1% be used with caution in patients with known bleeding tendencies, or who are receiving other medications, which may prolong bleeding time.
5.2 Delayed Healing Topical
5.2 Delayed Healing Topical NSAIDs, including NEVANAC 0.1%, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
5.3 Corneal Effects
5.3 Corneal Effects Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including NEVANAC 0.1%, and should be closely monitored for corneal health.
Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events, which may become sight threatening. Topical NSAIDs should be used with caution in these patients.
Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events.
5.4 Contact Lens Wear
5.4 Contact Lens Wear NEVANAC ® 0.1% should not be administered while using contact lenses.
Drug interactions
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Nepafenac at concentrations up to 300 ng/mL did not inhibit the in vitro metabolism of 6 specific marker substrates of cytochrome P450 (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4).
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of labeling: Increased Bleeding Time [see Warnings and Precautions (5.1)] Delayed Healing [see Warnings and Precautions (5.2)] Corneal Effects [see Warnings and Precautions (5.3)] Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure (IOP), and sticky sensation. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Harrow Eye, LLC at 833-4HARROW(427769) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure (IOP), and sticky sensation. These reactions occurred in approximately 5% to 10% of patients. Other ocular adverse reactions occurring at an incidence of approximately 1% to 5% included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, and vitreous detachment.
Some of these reactions may be the consequence of the cataract surgical procedure. Non-ocular adverse reactions reported at an incidence of 1% to 4% included headache, hypertension, nausea/vomiting, and sinusitis.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Teratogenic Effects Pregnancy Category C: Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. At this dose, the animal plasma exposure to nepafenac and amfenac was approximately 260 and 2400 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 80 and 680 times human plasma exposure for rabbits, respectively.
In rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased post-implantation loss, reduced fetal weights and growth, and reduced fetal survival. Nepafenac has been shown to cross the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response, NEVANAC 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Non-Teratogenic Effects Because of the known effects of prostaglandin biosynthesis inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of NEVANAC 0.1% during late pregnancy should be avoided.
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 Nursing Mothers Nepafenac is excreted in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NEVANAC 0.1% ophthalmic suspension is administered to a nursing woman.
Mechanism of action
12.1 Mechanism of Action After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.
US FDA labelPharmacokinetics
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours post dose, respectively, following bilateral topical ocular 3 times-daily dosing of nepafenac ophthalmic suspension, 0.1%. The mean steady-state C max for nepafenac and for amfenac were 0.310 ± 0.104 ng/mL and 0.422 ± 0.121 ng/mL, respectively, following ocular administration.
Nepafenac at concentrations up to 300 ng/mL did not inhibit the in vitro metabolism of 6 specific marker substrates of cytochrome P450 (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). Therefore, drug-drug interactions involving CYP-mediated metabolism of concomitantly administered drugs are unlikely.
Drug-drug interactions mediated by protein binding are also unlikely.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Nepafenac |
| PNF listing | Eye Suspension: 1 mg/mL, 5 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. NEVANAC · Harrow Eye, LLC [US FDA-approved label, version 3, November 5, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11b9a0cf-2a70-17ef-e063-6394a90a5d9e
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .